Abstract

Objective: Osteopenia of prematurity is an important cause of morbidity in preterm newborns. The aim of this study is to evaluate the clinical and laboratory findings and risk factors of osteopenia of prematurity in the newborns followed up in our unit.

Method: This study was a retrospective, cross-sectional study. Newborns with a gestational age of ≤ 32 weeks, a birth weight of ≤ 1500g were included in the study.

Results: The study included a total of 50 newborns. In patients with osteopenia of prematurity, invasive/noninvasive respiratory support, and duration of total parenteral nutrition (TPN) were longer, the incidence of necrotizing enterocolitis, red blood cell (RBC) transfusion rates, use of diuretics and proton pump inhibitors (PPI) were higher (p <0.05). Multiple regression analysis showed that prolonged duration of TPN was the most important risk factor for osteopenia of prematurity (OR: 1.484(1.009-2.182); p: 0.045).

Conclusion: This study shows that osteopenia of prematurity remains to be an important health problem in premature newborns. Patients with prolonged TPN infusions are at risk of developing osteopenia of prematurity. Adjustment of mineral supplements in parenteral nutrition according to calcium and phosphorus levels should be started early in life, and enteral nutrition should be encouraged by reducing the duration of TPN use. Further studies are needed to increase our awareness of osteopenia of prematurity and to clarify the relationship between PPI use and RBC transfusion and osteopenia of prematurity.

Keywords: Prematurity, osteopenia of prematurity, risk factor, proton pump inhibitor, red blood cell transfusion

Copyright and license

Copyright © 2023 The author(s). This is an open-access article published by Aydın Pediatric Society under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Hekimoğlu BS. Risk factors and clinical features of osteopenia of prematurity: Single-center experience. Trends in Pediatrics. 2023;4(1):24-30. https://doi.org/10.59213/TP.2023.46220

References

  1. İpek MŞ, Çekmez F, Berber M. Osteopenia of prematurity. Medeniyet Med J. 2015;30:41-50. https://doi.org/10.5222/MMJ.2015.041
  2. Chacham S, Pasi R, Chegondi M, Ahmad N, Mohanty SB. Metabolic bone disease in premature neonates: an unmet challenge. J Clin Res Pediatr Endocrinol. 2020;12:332-9. https://doi.org/10.4274/jcrpe.galenos.2019.2019.0091
  3. Avila-Alvarez A, Urisarri A, Fuentes-Carballal J, Mandiá N, Sucasas-Alonso A, Couce ML. Metabolic bone disease of prematurity: risk factors and associated short-term outcomes. Nutrients. 2020;12:3786. https://doi.org/10.3390/nu12123786
  4. O’Reilly P, Saviani M, Tou A, Tarrant A, Capra L, McCallion N. Do preterm bones still break? Incidence of rib fracture and osteopenia of prematurity in very low birth weight infants. J Paediatr Child Health. 2020;56:959-63. https://doi.org/10.1111/jpc.14852
  5. Jensen EA, White AM, Liu P, et al. Determinants of severe metabolic bone disease in very low-birth-weight infants with severe bronchopulmonary dysplasia admitted to a tertiary referral center. Am J Perinatol. 2016;33:107-13. https://doi.org/10.1055/s-0035-1560043
  6. Chan GM, Armstrong C, Moyer-Mileur L, Hoff C. Growth and bone mineralization in children born prematurely. J Perinatol. 2008;28:619-23. https://doi.org/10.1038/jp.2008.59
  7. Isojima T, Kushima R, Goishi K, et al. Mineral status of premature infants in early life and linear growth at age 3. Pediatr Int. 2015;57:864-9. https://doi.org/10.1111/ped.12657
  8. Xie LF, Alos N, Cloutier A, et al. The long-term impact of very preterm birth on adult bone mineral density. Bone Rep. 2018;10:100189. https://doi.org/10.1016/j.bonr.2018.100189
  9. Angelika D, Etika R, Mapindra MP, Utomo MT, Rahardjo P, Ugrasena IDG. Associated neonatal and maternal factors of osteopenia of prematurity in low resource setting: A cross-sectional study. Ann Med Surg (Lond). 2021;64:102235. https://doi.org/10.1016/j.amsu.2021.102235
  10. Aldemir EY, Kavuncuoğlu S, Akkelle BŞ, Karaatmaca B, Özbek S. The frequency of osteopenia in premature babies and the ethiological risk faktors. Turk Arch Pediatr. 2009;44:18-22.
  11. Mutlu M, Aktürk-Acar F, Kader Ş, Aslan Y, Karagüzel G. Risk factors and clinical characteristics of metabolic bone disease of prematurity. Am J Perinatol. 2023;40:519-24. https://doi.org/10.1055/s-0041-1729559
  12. Dursun M, Kavuncuoglu S. Effects of maternal vitamin D deficiency on osteopenia of prematurity in very low birth weight premature infants. Turk J Health S. 2021;2:31-5. https://doi.org/10.29228/tjhealthsport.54839
  13. Kavurt S, Demirel N, Yücel H, Unal S, Yıldız YT, Bas AY. Evaluation of radiologic evidence of metabolic bone disease in very low birth weight infants at fourth week of life. J Perinatol. 2021;41:2668-73. https://doi.org/10.1038/s41372-021-01065-y
  14. Kadioglu Simsek G, Buyuktiryaki M, Kanmaz Kutman HG, Canpolat FE. Alkaline phosphatase levels of preterm infants under 30 weeks of gestational age and its role in the diagnosis of osteopenia of prematurity. Annals of Medical Research. 2019;26:1688-91. https://doi.org/10.5455/annalsmedres.2019.07.421
  15. Bancalari E, Claure N. Definitions and diagnostic criteria for bronchopulmonary dysplasia. Semin Perinatol. 2006;30:164-70. https://doi.org/10.1053/j.semperi.2006.05.002
  16. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1-7. https://doi.org/10.1097/00000658-197801000-00001
  17. Chinoy A, Mughal MZ, Padidela R. Metabolic bone disease of prematurity-national survey of current neonatal and paediatric endocrine approaches. Acta Paediatr. 2021;110:1855-62. https://doi.org/10.1111/apa.15654
  18. Callenbach JC, Sheehan MB, Abramson SJ, Hall RT. Etiologic factors in rickets of very low-birth-weight infants. J Pediatr. 1981;98:800-5. https://doi.org/10.1016/s0022-3476(81)80852-9
  19. DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J. 1988;2:224-36.
  20. Cho SY, Park HK, Lee HJ. Efficacy and safety of early supplementation with 800 IU of vitamin D in very preterm infants followed by underlying levels of vitamin D at birth. Ital J Pediatr. 2017;43:45. https://doi.org/10.1186/s13052-017-0361-0
  21. Faienza MF, D’Amato E, Natale MP, et al. Metabolic bone disease of prematurity: diagnosis and management. Front Pediatr. 2019;7:143. https://doi.org/10.3389/fped.2019.00143
  22. Ognean ML, Boanta O, Gradinariu G. Metabolic bone disease of prematurity. Neonatology. 2010;2:29-53.
  23. Cakir M, Mungan I, Karahan C, Can G, Okten A. Necrotizing enterocolitis increases the bone resorption in premature infants. Early Hum Dev. 2006;82:405-9. https://doi.org/10.1016/j.earlhumdev.2005.10.015
  24. Ukarapong S, Venkatarayappa SKB, Navarrete C, Berkovitz G. Risk factors of metabolic bone disease of prematurity. Early Hum Dev. 2017;112:29-34. https://doi.org/10.1016/j.earlhumdev.2017.06.010
  25. Hall AR, Arnold CJ, Miller GG, Zello GA. Infant parenteral nutrition remains a significant source for aluminum toxicity. JPEN J Parenter Enteral Nutr. 2017;41:1228-33. https://doi.org/10.1177/0148607116638056
  26. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, et al. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab. 2003;88:3966-72. https://doi.org/10.1210/jc.2002-021548
  27. Raffaeli G, Manzoni F, Cortesi V, Cavallaro G, Mosca F, Ghirardello S. Iron homeostasis disruption and oxidative stress in preterm newborns. Nutrients. 2020;12:1554. https://doi.org/10.3390/nu12061554
  28. Treviño-Báez JD, Briones-Lara E, Alamillo-Velázquez J, Martínez-Moreno MI. Multiple red blood cell transfusions and iron overload in very low birthweight infants. Vox Sang. 2017;112:453-8. https://doi.org/10.1111/vox.12528
  29. Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26:2501-7. https://doi.org/10.1007/s00198-015-3168-0
  30. Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatr. 2020;174:543-51. https://doi.org/10.1001/jamapediatrics.2020.0007
  31. Wagner K, Wagner S, Susi A, Gorman G, Hisle-Gorman E. Prematurity does not increase early childhood fracture risk. J Pediatr. 2019;207:148-53. https://doi.org/10.1016/j.jpeds.2018.11.017
  32. Jo Y, Park E, Ahn SB, et al. A proton pump inhibitor’s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut Liver. 2015;9:607-14. https://doi.org/10.5009/gnl14135